For example, in a study of 175 breast cancer patients from the GeparQuattro trial, a >20% decrease in circulating HER2 throughout the course of treatment was associated with a 60% chance of pathologic complete response compared to patients where this decrease was not achieved through therapy (185). The gene discussed is ERBB2; the disease is breast cancer.